GRAL GRAIL Bio: Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan

Following the spin-off, GRAIL, Inc. (GRAL) updated its management, focusing on the commercialization of diagnostics, while laboratory processes and cloud data archives were transferred to external partners. The volatility of the quarterly EPS, which this chart from the GURU.Markets platform illustrates, demonstrates current financial stability, where 9.90 reflects the latest value of the metric. Growth prospects are linked to the expansion of the Galleri test and expected Medicare approval.

GRAL: Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan GRAIL 29.06.2024 - 12.11.2026

Ringkesan rincian data analitis GRAIL Bio (GRAL)

- rega saham lan prakiraan rega para ahli:

Rega saham GRAIL|GRAL - Prakiraan konsensus analis

- data kapitalisasi saham perusahaan:

Nilai pasar GRAIL Corp|GRAL - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham GRAIL|GRAL - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku grail.com|GRAL - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

- informasi bathi lan kelipatan valuasi:

GRAL - Bathi resik|Proyeksi bathi mangsa ngarep GRAIL, Inc.|GRAL - Periode bali modal bisnis|Rega marang bathi mangsa ngarep GRAIL Corp|GRAL - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan GRAIL Corp|GRAL - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) GRAIL|GRAL - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan grail.com|GRAL - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep GRAIL, Inc.

Analisis kabeh metrik perusahaan:GRAIL - GRAL

GRAIL, Inc. is scaling its business through the implementation of the innovative Galleri circulating DNA cancer diagnostics. Quarterly EPS growth measures the dynamics of net profit per share, reflecting the actual efficiency of capital management. This indicator allows investors to filter out speculative noise from operational success. For a biotech company, it is critical to see real profit growth rather than artificially inflated metrics. The quarterly EPS growth trajectory confirms the commercial viability of the technology.

Pesaing GRAIL, Inc.